Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crenolanib + docetaxel
- Development stage
- Unknown
- Lead developer
- AROG Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Crenolanib (CP-868596) is an orally bioavailable small molecule inhibitor that selectively targets class III receptor tyrosine kinases including platelet-derived growth factor receptor alpha (PDGFRα) and platelet-derived growth factor receptor beta (PDGFRβ), as well as FMS-like tyrosine kinase 3 (FLT3). It acts by inhibiting these kinases' signaling pathways, which are implicated in tumor angiogenesis and proliferation. Crenolanib is highly selective for PDGFR over other related kinases. Docetaxel is a taxoid antineoplastic agent that stabilizes microtubules and prevents their depolymerization, thereby inhibiting cell division and inducing apoptosis in cancer cells. The combination of crenolanib with docetaxel has been investigated in clinical trials for advanced solid tumors to assess safety and potential synergistic antitumor effects[1][2][3][5][6][8].
- Brand names
- Taxotere (for docetaxel)Docivyx (for docetaxel)
- Other names
- CP-868,596 + docetaxelcrenolanib besylate + docetaxel
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)PDGFRB (Platelet-derived growth factor receptor beta)MicrotubulePDGFRA (Platelet-derived growth factor receptor alpha)
Beyond the preview
Go deeper on crenolanib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crenolanib + docetaxel.